"Hämatologisch-onkologische Ambulanz Universitätsklinikum Halle"
Welcome,         Profile    Billing    Logout  
 7 Trials 
6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Al-Ali, Haifa Kathrin
NCT03306264 / 2018-003395-12: Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML

Checkmark Pharmacokinetic exposure equivalence and preliminary efficacy data from trial for MDS and CMML at ASH 2019
Checkmark Trial initiation in US (untreated high-risk MDS)
Checkmark [VIRTUAL] Use of Oral Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes
Recruiting
3
200
Europe, Canada, US, RoW
ASTX727, cedazuridine + decitabine, Dacogen, decitabine for injection
Astex Pharmaceuticals, Inc.
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
07/21
05/22
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Checkmark [VIRTUAL] Safety, Tolerability and Efficacy of Crenolanib Administered Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Patients with FLT3 Mutant AML
Checkmark SAFETY ANALYSIS OF INTRA-PATIENT DOSE - STUDY OF CRENOLANIB MAINTENANCE THERAPY IN PATIENTS WITH FLT3 MUTANT AML FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
Checkmark Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant
Checkmark INTRA-PATIENT DOSE-ESCALATION STUDY OF CRENOLANIB MAINTENANCE THERAPY IN PATIENTS WITH FLT3 MUTANT AML WHO HAD UNDERGONE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT)
Recruiting
3
322
Europe, Canada, US
Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
Arog Pharmaceuticals, Inc.
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
10/24
10/24
PONS, NCT03807479: Study in Patients With Chronic Leukemia, Where Previous Therapy Failed, and Who Will be Treated With Ponatinib as Second Line Therapy

Recruiting
2
54
Europe
Ponatinib, Iclusig
GWT-TUD GmbH, Incyte Biosciences International Sàrl
Leukemia, Myeloid, Chronic-Phase
06/22
05/24
NAUT, NCT02917720 / 2015-004998-33: 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in Patients With First or Second Unsuccessful Treatment Discontinuation in CML

Recruiting
2
200
Europe
TKI discontinuation, nilotinib
European LeukemiaNet, Heidelberg University, Ludwig-Maximilians - University of Munich
Chronic Myeloid Leukemia
09/25
09/26
NCT02719574 / 2017-001051-32: Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Checkmark [VIRTUAL] EFFECT OF OLUTASIDENIB (FT-2102) ON COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY MUTANT IDH1 ACUTE MYELOID LEUKEMIA. RESULTS FROM A PLANNED INTERIM ANALYSIS OF A PHASE 2 CLINICAL TRIAL
Checkmark [VIRTUAL] Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.
Checkmark Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine
Checkmark Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study
Checkmark FT-2102, AN IDH1M INHIBITOR, INDUCES MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) TREATED IN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY
More
Recruiting
1/2
500
Europe, Canada, US, RoW
FT-2102 (olutasidenib), Azacitidine, Vidaza, Cytarabine
Forma Therapeutics, Inc., Forma Therapeutics, Inc., FORMA Therapeutics, Inc., Forma Therapeutics INC
Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome
06/23
07/23
TRacKING, NCT04921553: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions

Recruiting
N/A
500
Europe, RoW
Data collection and quality of life questionnaire
Centre Leon Berard
Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation
06/25
06/25

Download Options